There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Medtronic (MDT – Research Report), Ayr Wellness (AYRWF – Research Report) and Trevi Therapeutics (TRVI – Research Report) with bullish sentiments.
Medtronic (MDT)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Medtronic today and set a price target of $100.00. The company’s shares closed last Thursday at $74.88.
According to TipRanks.com, Steed is a 3-star analyst with an average return of
Medtronic has an analyst consensus of Moderate Buy, with a price target consensus of $89.81, a 20.9% upside from current levels. In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $90.00 price target.
See today’s best-performing stocks on TipRanks >>
Ayr Wellness (AYRWF)
Echelon Wealth Partners analyst Andrew Semple maintained a Buy rating on Ayr Wellness today and set a price target of C$4.50. The company’s shares closed last Thursday at $1.99.
According to TipRanks.com, Semple is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Ayr Wellness has an analyst consensus of Strong Buy, with a price target consensus of $4.12, representing an 116.8% upside. In a report issued on November 2, Canaccord Genuity also maintained a Buy rating on the stock with a C$7.00 price target.
Trevi Therapeutics (TRVI)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics, with a price target of $6.00. The company’s shares closed last Thursday at $1.41, close to its 52-week low of $1.15.
According to TipRanks.com, Mamtani has 0 stars on 0-5 stars ranking scale with an average return of
Trevi Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.00, implying a 400.0% upside from current levels. In a report issued on November 2, JonesTrading also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDT:
- Acutus Medical to reduce workforce by 65% in corporate restructuring
- Medtronic call volume above normal and directionally bullish
- Medtronic announces four-year results from Evolut Low Risk Trial
- Medtronic receives FDA approval for extravascular defibrillator
- Medtronic price target lowered to $90 from $100 at Mizuho
